Encorafenib
- Generic Name
- Encorafenib
- Brand Names
- Braftovi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClFN7O4S
- CAS Number
- 1269440-17-6
- Unique Ingredient Identifier
- 8L7891MRB6
- Background
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most fr...
- Indication
Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorecta...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Unresectable Melanoma
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.